Pressemitteilung BoxID: 248395 (Nobel Biocare Deutschland GmbH)
  • Nobel Biocare Deutschland GmbH
  • Stolberger Straße 200
  • 50933 Köln
  • Ansprechpartner
  • Süha Demokan
  • +41 (43) 21142-30

Nobel Biocare signs syndicated loan facility

(PresseBox) (Zürich, Switzerland, ) Nobel Biocare announced today the closing of a EUR 330 million committed syndicated banking facility with 6 international banks and a maturity of 3 years. The facility is designed to optimize current funding and serves also as a backup line to increase the company's financial flexibility going forward.

Dirk Kirsten, CFO, said: "In the current financial markets environment the successful closing of such a transaction is an important achievement. This is testimony of our leading market position with intact long-term perspectives, our strong balance sheet and a strong operating cash flow in 2008".

Nobel Biocare Deutschland GmbH

Nobel Biocare is a medical devices group and the world leader in innovative esthetic dental solutions with its key brands NobelActive(TM) , Brånemark System®, NobelReplace(TM) , NobelSpeedy(TM) , Replace Select (dental implants), NobelProcera® (individualized dental prosthetics), NobelGuide(TM) (complete patient rehabilitation program) and NobelSmile(TM) (patient education and awareness program). Nobel Biocare is a full solution provider for restorative esthetic dentistry, offering a wide range of innovative Crown & Bridge & Implant products, as well as training and education, patient information and clinically documented treatment concepts. Nobel Biocare has over 2,500 employees and recorded revenue of EUR 619.2 million in 2008. The Company is domiciled and headquartered in Zurich, Switzerland. Production takes place at six production sites located in Sweden, the US, Japan and Israel. Nobel Biocare has 37 direct sales organizations. The shares of the parent company Nobel Biocare Holding AG are listed on the SIX Swiss Exchange.